表紙
市場調査レポート

心房細動 (AF) の予測:主要18市場

Atrial Fibrillation Forecast In 18 Major Markets 2015 -2025

発行 Black Swan Analysis 商品コード 342571
出版日 ページ情報 英文 72 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
心房細動 (AF) の予測:主要18市場 Atrial Fibrillation Forecast In 18 Major Markets 2015 -2025
出版日: 2015年10月27日 ページ情報: 英文 72 Pages
概要

心房細動 (AF) は、上室性不整脈の最も一般的なタイプです。異常な電気信号が心房に送られると、心房細動 (AF) が引き起こされます。

当レポートでは、主要18市場 (米国、フランス、ドイツ、イタリア、スペイン、英国、ブラジル、日本、インド、メキシコ、トルコ、カナダ、オーストラリア、オランダ、アルゼンチン、ロシア、中国、韓国) における心房細動 (AF) の現在の患者数 (性別、年齢コホート別) について調査分析し、現在の有病率のほか、疾患の概要、危険因子、疾患の診断と予後、主な症状や合併症など、体系的な情報を提供しています。

図表

イントロダクション

病因

危険因子と予防

疾患の診断

変異:地域/民族別

疾患予後と臨床経過

疾患に関連する主な合併症/特徴

患者数を定量化する手法

心房細動 (AF) の有病率トップライン

心房細動 (AF) の主なタイプと心臓の機能

  • 主なタイプの分類
  • 心房細動 (AF) に関連する心臓の状態

心房細動 (AF) の治療の種類

略語

関連出版

オンラインによる患者ベースのデータベース

患者ベースの製品

オンラインによる価格データとプラットフォーム

参考文献

付録

目次
Product Code: ATFB0011015

Atrial Fibrillation (AF) is the most prevalent type of supraventricular arrhythmia. AF occurs when abnormal electric signals are sent to the atria, which cause them to contract quickly and irregularly. For many patients, the condition is largely asymptomatic, however when symptoms become bothersome and frequent, intervention is required to restore normal rhythm.

This report provides the current prevalent population for AF across 18 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Mexico, Turkey, Canada, Australia, Netherlands, Argentina, Russia, China and South Korea) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the classification and patient treatment options for AF. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AF include:

  • Hypertension
  • CHF/ CAD and other structural cardiac diseases
  • Diabetes
  • Mitral Stenosis / other valvular disorders
  • COPD
  • Stroke
  • Rheumatic Heart Disease

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global AF's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of AF and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on AF's prevalent population.
  • Identify sub-populations within AF which require treatment.
  • Gain an understanding of the specific markets that have the largest number of AF patients.

Coverage

  • U.S.
  • United Kingdom
  • France
  • Germany
  • Italy
  • Spain
  • Japan
  • U.K.
  • China
  • India
  • Turkey
  • Canada
  • Australia
  • Netherland
  • Argentine
  • Russia
  • Korea
  • Mexico

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/ Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
    • Additional data available on request
  • Top-Line Prevalence for Atrial Fibrillation
  • Main Type and Cardiac Features of AF
    • AF Main Type Classification
    • Associated Cardiac Conditions of AF
  • Type of AF Treatment
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Figures:

  • AF prevalence rates for 2015
  • ESC Guidelines for Management of AF

List of Tables

  • Prevalence of AF, total (000s)
  • Prevalence of AF, males (000s)
  • Prevalence of AF, females (000s)
  • Classification of AF by duration of episode, total (000s)
  • Type of AF classified by valvular or non-valvular, total (000s)
  • AF by 5 year incidence of stroke event, total (000s)
  • AF classified by type of ischaemic stroke mechanism, total (000s)
  • Prevalence of hypertension in AF patients, total (000s)
  • Prevalence of CAD in AF patients, total (000s)
  • Prevalence of valvular heart disease in AF patients, total (000s)
  • Prevalence of left ventricular hypertrophy in AF patients, total (000s)
  • AF patients taking anti-arrhythmic drugs, total (000s)
  • AF patients taking Vitamin K antagonists, total (000s)
  • AF patients taking anti-platelet therapy, total (000s)
  • AF patients with a pacemaker/ ICD implant, total (000s)
  • Catheter ablation in AF patients, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of AF by 5-yr age cohort, males (000s)
  • USA Prevalence of AF by 5-yr age cohort, females (000s)
  • France Prevalence of AF by 5-yr age cohort, males (000s)
  • France Prevalence of AF by 5-yr age cohort, females (000s)
  • Germany Prevalence of AF by 5-yr age cohort, males (000s)
  • Germany Prevalence of AF by 5-yr age cohort, females (000s)
  • Italy Prevalence of AF by 5-yr age cohort, males (000s)
  • Italy Prevalence of AF by 5-yr age cohort, females (000s)
  • Spain Prevalence of AF by 5-yr age cohort, males (000s)
  • Spain Prevalence of AF by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of AF by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of AF by 5-yr age cohort, females (000s)
  • Brazil Prevalence of AF by 5-yr age cohort, males (000s)
  • Brazil Prevalence of AF by 5-yr age cohort, females (000s)
  • Japan Prevalence of AF by 5-yr age cohort, males (000s)
  • Japan Prevalence of AF by 5-yr age cohort, females (000s)
  • India Prevalence of AF by 5-yr age cohort, males (000s)
  • India Prevalence of AF by 5-yr age cohort, females (000s)
  • Mexico Prevalence of AF by 5-yr age cohort, males (000s)
  • Mexico Prevalence of AF by 5-yr age cohort, females (000s)
  • Turkey Prevalence of AF by 5-yr age cohort, males (000s)
  • Turkey Prevalence of AF by 5-yr age cohort, females (000s)
  • Canada Prevalence of AF by 5-yr age cohort, males (000s)
  • Canada Prevalence of AF by 5-yr age cohort, females (000s)
  • Australia Prevalence of AF by 5-yr age cohort, males (000s)
  • Australia Prevalence of AF by 5-yr age cohort, females (000s)
  • Netherlands Prevalence of AF by 5-yr age cohort, males (000s)
  • Netherlands Prevalence of AF by 5-yr age cohort, females (000s)
  • Argentina Prevalence of AF by 5-yr age cohort, males (000s)
  • Argentina Prevalence of AF by 5-yr age cohort, females (000s)
  • Russia Prevalence of AF by 5-yr age cohort, males (000s)
  • Russia Prevalence of AF by 5-yr age cohort, females (000s)
  • China Prevalence of AF by 5-yr age cohort, males (000s)
  • China Prevalence of AF by 5-yr age cohort, females (000s)
  • South Korea Prevalence of AF by 5-yr age cohort, males (000s)
  • South Korea Prevalence of AF by 5-yr age cohort, females (000s)
Back to Top